2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium

KEYNOTE-590 extended follow-up shows pembro + chemo maintains survival in advanced oesophageal cancer

Elaine Soliven, 20220312000000

First-line treatment with pembrolizumab + chemotherapy maintains overall survival (OS) and progression-free survival (PFS) in patients with advanced or metastatic oesophageal cancer, according to an additional 12-month follow-up of the KEYNOTE-590* study presented at ASCO GI 2022.

CheckMate-649: Upfront NIVO + chemo maintains survival benefit in advanced oesophagogastric cancer

Pearl Toh, 20220305150100

Upfront treatment with nivolumab plus chemotherapy continues to yield significant survival benefit compared with chemotherapy alone in patients with advanced GC/GEJC/EAC* after 24 months, regardless of their PD-L1 combined positive score (CPS), according to long-term data from the CheckMate-649 trial presented at GICS 2022.

KEYNOTE-394 a win for Asians with advanced HCC

Elvira Manzano, 20220301000000

Combining pembrolizumab with best supportive care (BSC) improved survival and response when used as second-line therapy in Asians with advanced hepatocellular carcinoma (HCC).

STRIDE regimen boosts OS in unresectable HCC

Roshini Claire Anthony, 20220225180001

The addition of tremelimumab to durvalumab (STRIDE regimen) in the first-line setting improved overall survival (OS) compared with sorafenib in patients with advanced unresectable hepatocellular carcinoma (HCC), according to results of the phase III HIMALAYA trial.

Lenvatinib-TACE combo a new first-line treatment alternative for advanced liver cancer?

Audrey Abella, 20220223104843

In individuals with advanced hepatocellular carcinoma (HCC), the combination of transarterial chemoembolization (TACE) and lenvatinib as first-line treatment led to improved survival outcomes as opposed to lenvatinib monotherapy, according to findings of the phase III LAUNCH* trial.

Durvalumab + chemo: A new SoC for advanced BTC?

Roshini Claire Anthony, 20220222180001

Patients with advanced biliary tract cancer (BTC) who receive durvalumab in addition to standard of care (SoC) gemcitabine plus cisplatin chemotherapy in the first-line setting have a reduced risk of death compared with those receiving SoC alone, according to results of the TOPAZ-1 study presented at ASCO GI 2022.

Triplet chemo bests doublet regimen for ESCC

Audrey Abella, 20220214100000

A triplet chemotherapeutic (CT) regimen comprising docetaxel, cisplatin, and 5-fluororacil (5-FU; DCF) outdid a doublet regimen comprising CF as neoadjuvant treatment for locally advanced oesophageal squamous cell carcinoma (ESCC), the phase III JCOG*1109 NExT study suggests.

Adjuvant S-1 ups survival in resected biliary tract cancer

Pearl Toh, 20220205150100

Giving adjuvant S-1 to patients with curatively resected biliary tract cancer (BTC) significantly improves survival compared with observation following surgery, according to the ASCOT trial presented in the 2022 ASCO Gastrointestinal Cancers Symposium (GICS).